• 1
    Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37(Suppl. 8): S466.
  • 2
    Fiorica F, Di Bona D, Schepis F et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 2004; 53: 92530.
  • 3
    Osaka Y, Takagi Y, Tsuchida A et al. Concurrent preoperative chemoradiotherapy for stage III or IV esophageal squamous carcinoma. Oncol Rep 2004; 12: 11216.
  • 4
    Lee JL, Park SI, Kim SB et al. A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol 2004; 15: 94754.
  • 5
    Burmeister BH, Smithers BM, Gebski V et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 2005; 6: 65968.
  • 6
    Tepper J, Krasna MJ, Niedzwiecki D et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008; 26: 108692.
  • 7
    van Hagen P, Hulshof MC, van Lanschot JJ et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 207484.
  • 8
    Berger AC, Farma J, Scott WJ et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 2005; 23: 43307.
  • 9
    Kim MK, Kim SB, Ahn JH et al. Treatment outcome and recursive partitioning analysis-based prognostic factors in patients with esophageal squamous cell carcinoma receiving preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys 2008; 71: 72534.
  • 10
    Donahue JM, Nichols FC, Li Z et al. Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg 2009; 87: 3928; discussion 8–9.
  • 11
    Kleinberg L, Forastiere AA. Chemoradiation in the management of esophageal cancer. J Clin Oncol 2007; 25: 41107.
  • 12
    Geh JI. The use of chemoradiotherapy in oesophageal cancer. Eur J Cancer 2002; 38: 30013.
  • 13
    Budhu A, Forgues M, Ye QH et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006; 10: 99111.
  • 14
    Seike M, Yanaihara N, Bowman ED et al. Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. J Natl Cancer Inst 2007; 99: 125769.
  • 15
    Suzuki Y, Mimura K, Yoshimoto Y et al. Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Cancer Res 2012; 72: 396776.
  • 16
    Sobin LH. TNM Classification of Malignant Tumours, 6th edn. New York: Wiley-Liss, 2002; 99103.
  • 17
    The Japanese Society for Esophageal Disease. Guidlines for the Clinical and Pathologic Studies on Carcinoma of the Esophagus, 9th edn. In: Isono K, ed. Tokyo: Kanehara Shuppan, 2001.
  • 18
    Kikuchi S, Honda K, Tsuda H et al. Expression and gene amplification of actinin-4 in invasive ductal carcinoma of the pancreas. Clin Cancer Res 2008; 14: 534856.
  • 19
    Kojima T, Hashimoto J, Kato K et al. Feasibility study of neoadjuvant chemoradiotherapy with cisplatin plus 5-fluorouracil and elective nodal irradiation for stage II/III esophageal squamous cell carcinoma. J Clin Oncol 2012; 37(Suppl. 4): Abstract 130.
  • 20
    Honda K, Yamada T, Endo R et al. Actinin-4, a novel actin-bundling protein associated with cell motility and cancer invasion. J Cell Biol 1998; 140: 138393.
  • 21
    Honda K, Yamada T, Hayashida Y et al. Actinin-4 increases cell motility and promotes lymph node metastasis of colorectal cancer. Gastroenterology 2005; 128: 5162.
  • 22
    Honda K, Hayashida Y, Umaki T et al. Possible detection of pancreatic cancer by plasma protein profiling. Cancer Res 2005; 65: 1061322.
  • 23
    Aickin M, Gensler H. Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods. Am J Public Health 1996; 86: 7268.
  • 24
    Zingg U, Forberger J, Rajcic B, Langton C, Jamieson GG. Association of C-reactive protein levels and long-term survival after neoadjuvant therapy and esophagectomy for esophageal cancer. J Gastrointest Surg 2010; 14: 4629.
  • 25
    Shimada H, Nabeya Y, Okazumi S et al. Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol 2003; 83: 24852.
  • 26
    Yamaji T, Inoue M, Sasazuki S et al. Fruit and vegetable consumption and squamous cell carcinoma of the esophagus in Japan: the JPHC study. Int J Cancer 2008; 123: 193540.
  • 27
    Jones SA, Horiuchi S, Topley N, Yamamoto N, Fuller GM. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J 2001; 15: 4358.
  • 28
    Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 2011; 121: 337583.
  • 29
    Garbers C, Thaiss W, Jones GW et al. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem 2011; 286: 4295970.
  • 30
    Oka M, Iizuka N, Yamamoto K et al. The influence of interleukin-6 on the growth of human esophageal cancer cell lines. J Interferon Cytokine Res 1996; 16: 10016.
  • 31
    Fujiwara H, Suchi K, Okamura S et al. Elevated serum CRP levels after induction chemoradiotherapy reflect poor treatment response in association with IL-6 in serum and local tumor site in patients with advanced esophageal cancer. J Surg Oncol 2011; 103: 628.
  • 32
    Shimada H, Takeda A, Nabeya Y et al. Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma. Cancer 2001; 92: 6639.
  • 33
    Shimada H, Kitabayashi H, Nabeya Y et al. Treatment response and prognosis of patients after recurrence of esophageal cancer. Surgery 2003; 133: 2431.
  • 34
    Jee SH, Shen SC, Chiu HC, Tsai WL, Kuo ML. Overexpression of interleukin-6 in human basal cell carcinoma cell lines increases anti-apoptotic activity and tumorigenic potency. Oncogene 2001; 20: 198208.
  • 35
    Suchi K, Fujiwara H, Okamura S et al. Overexpression of Interleukin-6 suppresses cisplatin-induced cytotoxicity in esophageal squamous cell carcinoma cells. Anticancer Res 2011; 31: 6775.
  • 36
    Efimova EV, Liang H, Pitroda SP et al. Radioresistance of Stat1 over-expressing tumour cells is associated with suppressed apoptotic response to cytotoxic agents and increased IL6-IL8 signalling. Int J Radiat Biol 2009; 85: 42131.
  • 37
    Leu CM, Wong FH, Chang C, Huang SF, Hu CP. Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways. Oncogene 2003; 22: 780918.
  • 38
    Sun Y, Moretti L, Giacalone NJ et al. Inhibition of JAK2 signaling by TG101209 enhances radiotherapy in lung cancer models. J Thorac Oncol 2011; 6: 699706.